AEON Biopharma

Leadership includes CEO Robert Bancroft (appointed April 2025), CMO Dr. Chad Oh and CFO John Bencich (appointed March 2026). The team combines clinical neurotoxin expertise and capital markets experience that is appropriate for a biosimilar pathway and serial fundraising.

However, track record within AEON includes unsuccessful migraine readouts prior to the strategic pivot, and incentive alignment must be balanced against dilution risk. On net we view management as competent for the chosen path but unproven in delivering regulatory approval and commercialization.